A proportion of cells expressing mutant or amplified BRAF become dependent on BRAF inhibition for a selective advantage, and cessation of drug administration leads to tumor regression; a staggered regimen has been shown to delay onset of resistance in both mice and human xenograft cell lines [123]. This evidence concerns the gene BRAF and neoplasm.